The Board of Oslo Cancer Cluster is made up of ten highly skilled and experienced member representatives whom reflect the oncology value chain from basic research to globally marketed products, including patient organizations.
Øyvind Kongstun Arnesen
Øyvind Kongstun Arnesen was appointed chairman of the board in 2018.
Kongstun Arnesen is a MD with both more than ten years of clinical experience and experience from the Pharmaceutical Industry. He is currently the CEO at Ultimovacs, and has held positions such as Medial Director Norway BMS, Medical Director and Head of Clinical Operations at Boehringer Ingelheim.
He is a member of The National Commission for the Investigation of Research Misconduct in Norway and at the Norwegian Pharmaceutical Industry Association.
Ludvik Sandnes has more than 40 years of experience from international corporate finance, banking and asset management.
He is Chairman of the Board of Nordic Nanovector ASA, listed on the Oslo Stock Exchange, and board member of Oncoinvent AS, Oslo Cancer Cluster, Godthaab Helse og Rehabilitering and Pioner Fonds AS.
Ludvik holds degrees as Siviløkonom and Certified European Financial Analyst (AFA) from the Norwegian School of Economics and Business Administration.
Sandnes became a member of the Oslo Cancer Cluster board in 2015.
Benedikte Thunes Akre
Benedikte Thunes Akre has a Cand. Pharm degree from the University of Oslo as well as Bachelor Degree in Biomedical Sciences. She has a long line of experience working within the pharmaceutical industry including preclinical pharmacology, regulatory, safety, marketing and medical affairs.
Thunes Akre has worked for Bristol-Myers Squibb the last 18 years and was until recently part of the Global Medical Affairs organization within Immuno-Oncology. She is currently working in Astra Zeneca as Medical Director, Nordics & Baltics.
Line Bjørge holds the position as medical director in Gynecologic oncology at Helse Bergen HF and is professor in Obstetrics and gynecology and associated investigator at Center for Cancer Biomarkers (CCBIO) at the University of Bergen (UiB).
She earned her MD degree from UiB, her PhD degree from UiB and University of Helsinki and her MBA degree from ESSEC, Paris and Mannheim Business School, Mannheim. Her clinical (in Obstetrics and Gynecology, and in Gynecologic Oncology) and post-doctoral research training in cancer immunology took place both in Norway and abroad (Helsinki, Innsbruck and Groningen).
She has a comprehensive publication list, and her present research activities cover both translational projects as well as clinical trials. She is partner in two H2020 funded projects.
She holds the position as leader for Onkologisk Forum, is member of the board for The Norwegian Cancer Society and is one of two gynecologists in the newly established national second-opinion panel for incurable diseases. She is also active in in the Nordic Society for Gynecologic Oncology, and from 2018 she holds the position as president elect.
Jónas Einarsson, M.D., is the CEO of the Radium Hospital Research Foundation. He is also on the Management Team of the Oslo Cancer Cluster Innovation Park. Einarsson is the founder and former CEO and Chairman of the board of Oslo Cancer Cluster and the Oslo Cancer Cluster Innovation Park.
The Radium Hospital Research Foundation is an experienced pre-seed investor and project developer focused on cancer. Their focus is on startup companies based on Norwegian research within immunoncology. During his time as CEO, Einarsson has been involved in more than 20 startups.
Einarsson was the CEO and Chairman of the board of Norway’s first private hospital, Oslo Private Sykehus AS. He acted as General Practitioner and Chief Medical Officer of Lardal Municipality for ten years.
Per Morten Sandset
Per Morten Sandset is a Senior Consultant in hematology at the Oslo University Hospital and a professor in thrombosis research at the University of Oslo.
He has previously been head of the Department of Hematology and Deputy Director of the Medical Division at Ullevål University Hospital and Director of Research, Innovation and Education of the southeastern Norway Health Region.
He is currently Vice-Rector at the University of Oslo with responsibilities for research and innovation including the life sciences activities of the university. Sandset has published more than 315 original publications and supervised 30 PhD students.
Cathrine M. Lofthus
Cathrine M. Lofthus is the CEO at the Norwegian South East Regional Health Authority (Helse Sør-Øst RHF). She has previously held several leading positions at Aker University Hospital and at Oslo University Hospital.
Lofthus is a qualified doctor from the University of Oslo, where she also completed a PhD in endocrinology. She also holds qualifications in economy, administration and leadership, and has experience from the health sector as a clinician, researcher and leader.
Lofthus also holds directorships in Norsk helsenett and KLP, in addition to being a member of the board of National e-Health.
Ole Dahlberg has more than 15 years’ international life science management experience. He joined the board of Oslo Cancer Cluster in June 2016.
Dahlberg is Managing Director for Thermo Fisher Norway and in the leadership group of License- and Commercial Supply in Thermo Fisher Scientic.
Gunhild M. Mælandsmo
Gunhild M. Mælandsmo is the head of Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital where she also is heading the “Metastasis Biology and Experimental Therapeutics” research group. She is a Professor at Faculty of Health Sciences, University of Tromsø.